Member Info for Malachi

Sorry
too long to include all. Worth reading on Angle site

For immediate release


28 April 2020



ANGLE plc ("the Company")



BUSINESS UPDATE



Progress across multiple fronts



In-house capability developed to determine CTC PDL1 status for immunotherapy trials



COVID-19 highlights crucial need for liquid biopsy for cancer patients





ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to provide an update on the Company's progress since the COVID-19 lock down started.



As announced on 31 March 2020, ANGLE's operations in the UK, Canada and USA have been impacted by the COVID-19 pandemic and the resulting Government directives, notably in relation to completion of the remaining analytical samples required for the Company's FDA submission and patient enrolment for the Company's ovarian cancer clinical verification study.



Following a period of unanticipated disruption and delay caused by COVID-19, a key focus during lock down is on finalising the significant amount of written documentation and analysis for the FDA submission, so that this can be rapidly submitted once the remaining analytical samples are available and analysed. This is progressing well and it is expected that submission can be made promptly once restrictions ease so that we can secure the remaining healthy volunteer blood samples needed to complete the analytical study work.



The Company has adopted a proactive approach to the lock down advancing on multiple fronts and developing some new initiatives.



R&D, product development and engineering work



The Company's Guildford UK laboratories are now operating with a skeleton crew, double shift operation with enhanced social distancing and other precautions in place to enable the progression of experimental and engineering work that does not require access to donor blood. This work is supporting key Parsortix® system R&D, product development and engineering activities.



Ovarian cancer test



The Company's Toronto Canada laboratories are open for technical personnel who cannot work from home, also with double shift operation and enhanced social distancing and other precautions in place. This is enabling HyCEAD® Ziplex™ analytical and assay verification work for the ovarian cancer test to progress.



The University of Rochester Medical Center Wilmot Cancer Institute, New York has temporarily ceased patient enrolment. In the absence of the current clinical verification study samples, the decision has been taken to analyse the second retained samples from the previous ovarian cancer clinical study. This was a duplicate blood sample from every patient that was processed on Parsortix and then stored as a frozen lysate. Analysis of these samples will use the further optimised HyCEAD Ziplex cancer gene panel planned for the current study.
There is an RNS today updating progress during COVID delays. It is upbeat.

Then FO and sell

Yes, this is a large swing in the absence of news. There can only be one news item that everyone is waiting for and that is FDA approval, which is months away.

Sadly it will not.

No, nothing surprises any of us anymore.

?

The 'test' reported on BBC refers to examination of DNA fragments found in whole blood, and appears to be a cancer screening test. This does not compete with Parsortix which isolates intact CTCs and which allows extremely detailed examination of all aspects of the a malignancy. I have never thought of Parsortix as a cancer screening test, though in a study reported some time ago in an RNS I remember a 'normal' control in a breast ca study being found to have circulating breast cancer cells

Just hang on in here. this is a winner with no competition. My biggest punt by far, and i am happy even to add at these silly prices

Yes, new phone ordered 18 h ago now in my hands. No brainer, no waste of petrol going into town, and ££££ cheaper. but the centre of my local county town has lost M&S and many more, giving way to umpteen phone shops, betting shops, charity shops etc,. So there is a downside.
Sorry, nothing whatever to do with AFC.......

Children! Behave yourselves!

What splendid rubbish. A good laugh for a Monday morning. How can folk be so credulous? Just look at the titles of the other quoted articles to see where these sad folk are coming from.

I also find it odd, sad even that boards have had to tolerate the likes of Dolphin and his comrade in arms, Pomander a year or two back before suddenly b*ggering off. It takes all sorts. Then there was BMac on AFC who wrote very long admonitory essays before Christmas, largely repetitive, on why AFC was going to go south. It seems not to have followed his advice. And now Yellow. The yellow flag used to be flown by ships reaching port that had cases of infectilous disease on board, advising all and sundry to steer clear. A message here, perhaps?

It was badly written and that has caused confusion. "PowerHouse will, if Peel exercises the option, receive £500,000 as a one-off fee for granting Peel exclusive rights to develop the DMG® Technology in the UK. On an ongoing basis, PowerHouse will then be entitled to a licence fee of approximately £500,000 for each DMG® plant that Peel develops, which will become payable when a unit becomes operational" Wrong; PHE develops the technology, Peel uses it on sites in UK. PHE will have an annual licence fee of £500000. Adding the word ANNUAL to licence fee would have made it clear.

I have a feeling that battery powered EVs will be somewhat analogous to canals in the C18. Everyone bust a gut to build canals everywhere, and 30 years later along came railways. When the country is well and truly festooned with charging points, at grotesque cost, they will be redundant, and we will all be running on hydrogen or ammonia.

I find it odd that if SYM is the partner to this deal that we have not seen an quote from SYM at the borttom of the RNS, something along the usual lines of 'important collaboration', 'delighted to work with Itaconix' etc,. etc,. Any publicity is good publicity.

There is nothing in AGL that justifies the SP fall; buying opportunity for some.

Fantastic read, but, "following approval from the U.S. Food & Drugs Administration (FDA) for its d2p antimicrobial technology, for use in polyethylene (LLDPE) film for wrapping bread". Is this approval really only for wrapping bread? What about all other foodstuffs that get pre-wrapped. Does that really require separate approval? Seems odd not to make it a generic food wrapping approval.

jgbb123. I did not realise that our opinion of your dear leader were shared N of the border!

>£1M bought yesterday.